Calidi Biotherapeutics, Inc. (CLDI) Form 8-K — Aug 13, 2026
Calidi Biotherapeutics reported a Q2 2026 net loss attributable to common stockholders of $4.2 million, or $2.94 per share, improved from a $5.7 million loss, or $31.75 per share, a year earlier; per-share figures reflect the 1-for-16 reverse stock split completed in July 2026. The key catalyst is positive pre-IND feedback from the FDA for CLD-401, the lead candidate from Calidi's RedTail oncolytic virus platform, with agreement on the development path toward a first-in-human study targeting first patient dosing in Q1 2027. The company also presented new CLD-501 data at the 2026 ASCO meeting demonstrating in situ delivery of a TROP-2-targeted T-cell engager.
Key figures
- Total Assets
- 7204000
- Cash Position
- 4071000
- Total equity
- 3133000
- Restricted cash
- 200000
- Cash dec 31 2025
- 5600000
- Total liabilities
- 4071000
- Ga expense q2 2025
- 3071000
- Ga expense q2 2026
- 1592000
- Reverse split ratio
- 1-for-16 (completed July 2026)
- Rnd expense q2 2025
- 2593000
- Rnd expense q2 2026
- 2558000
- Ga expense reduction
- 1500000
- Ga expense reduction pct
- 48%
- First patient dosing target
- Q1 2027
- Weighted avg shares q2 2026
- 1416000
- Weighted avg shares q2 2025 split adjusted
- 180000
Price after filing
Close on the filing date to close N calendar days later (from $1.54). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.